IID-11.3 Data Details

The National Immunization Survey-Teen (NIS-Teen) collects vaccination information for adolescents aged 13–17 years in the 50 states, the District of Columbia, selected areas, and the U.S. Virgin Islands, using a random-digit-dialed sample of landline and, starting in 2011, cellular telephone numbers. Parent/guardian respondents provide vaccination and sociodemographic information on adolescents in their care. After the parent/guardian grants permission to contact their child's vaccination provider, a questionnaire is mailed to that provider to obtain a vaccination history from the medical record. Data for this measure are restricted to adolescents aged 13–15 and weighted to represent the population of adolescents age 13–15, with adjustments for households with multiple telephone lines and mixed telephone use (landline and cellular), household nonresponse, and exclusion of households without telephone service.

In 2005, the Advisory Committee on Immunization Practices (ACIP) recommended the routine vaccination of adolescents aged 11–12 years at the preadolescent health care visit and for adolescents before high school entry. In 2008, the ACIP expanded its recommendations to the routine administration of meningococcal vaccine at 11–12 years of age and 13–18 years of age if not previously vaccinated. In 2011, the ACIP recommended that a single dose of vaccine be administered at age 11 or 12 years, with a booster dose at age 16 years for persons who receive the first dose before age 16 years.

This measure tracks the proportion of adolescents aged 13–15 years receiving at least 1 of the meningococcal conjugate vaccine (MenACWY) and meningococcal-unknown type vaccine.

The National Immunization Survey-Teen (NIS-Teen) collects vaccination information for adolescents aged 13–17 years in the 50 states, the District of Columbia, selected areas, and the U.S. Virgin Islands, using a random-digit-dialed sample of landline and, starting in 2011, cellular telephone numbers. Parent/guardian respondents provide vaccination and sociodemographic information on adolescents in their care. After the parent/guardian grants permission to contact their child's vaccination provider, a questionnaire is mailed to that provider to obtain a vaccination history from the medical record. Data for this measure are restricted to adolescents aged 13–15 and weighted to represent the population of adolescents age 13–15, with adjustments for households with multiple telephone lines and mixed telephone use (landline and cellular), household nonresponse, and exclusion of households without telephone service.

In 2005, the Advisory Committee on Immunization Practices (ACIP) recommended the routine vaccination of adolescents aged 11–12 years at the preadolescent health care visit and for adolescents before high school entry. In 2008, the ACIP expanded its recommendations to the routine administration of meningococcal vaccine at 11–12 years of age and 13–18 years of age if not previously vaccinated. In 2011, the ACIP recommended that a single dose of vaccine be administered at age 11 or 12 years, with a booster dose at age 16 years for persons who receive the first dose before age 16 years.

This measure tracks the proportion of adolescents aged 13–15 years receiving at least 1 of the meningococcal conjugate vaccine (MenACWY) and meningococcal-unknown type vaccine.